Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.95 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.95 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutathione SCHEMBL14125840 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL2124417 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL22115882 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL14125841 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL2124421 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL183281 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL183280 | 1.00 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL20542219 | 0.99 | PTGS1 (0.92) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL20542215 | 0.99 | PTGS1 (0.92) | PTGS1GSTK1GLO1NOD1SLC7A11 | |
| Glutathione SCHEMBL13105609 | 0.97 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629769-A1 | CYSTEINE AND FOOD INTAKE | Nestec S.A. (CH) | 2013-08-28 | — | — | EP | claimed |
| WO-2012052463-A1 | CYSTEINE AND FOOD INTAKE | NESTEC S.A. (CH) | 2012-04-26 | — | — | WO | claimed |
| CN-114099484-A | Application of tetrahydrocurcumin in preparation of medicine for preventing and/or treating type 2diabetes and non-alcoholic fatty liver disease | 四川省中医药转化医学中心 | 2022-03-01 | — | — | CN | disclosed |
| US-11135228-B2 | Cysteinyl-proresolving mediators that promote resolution of infection and organ protection | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| CN-108883198-A | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | 卫材研究发展管理有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-106188151-B | A kind of ionic phosphorescent iridium complex probe based on pyridiniujm and preparation method thereof and biologic applications | 南京邮电大学 | 2018-07-31 | — | — | CN | disclosed |
| CN-107849121-A | End-blocking and uncapped antibody cysteine, and its purposes in antibody drug is conjugated | 辉瑞公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20170258806-A1 | OXYLIPIN-PEPTIDE CONJUGATED MEDIATORS THAT PROMOTE RESOLUTION OF INFECTION, ORGAN PROTECTION AND TISSUE REGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-14 | — | — | US | disclosed |
| CN-105828840-A | 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds and methods of use and treatment | 基因泰克公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-105636612-A | 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds, and methods of use and treatment | GENENTECH INC | 2016-06-01 | — | — | CN | disclosed |
| WO-2015027116-A1 | DIAGNOSTIC AND PREDICTIVE METABOLITE PATTERNS FOR DISORDERS AFFECTING THE BRAIN AND NERVOUS SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2010099479-A1 | NON SEPARATION ASSAYS WITH SELECTIVE SIGNAL INHIBITORS | BECKMAN COULTER, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| CN-100464743-C | N-acetylcysteine compositions and methods for the treatment and preventino of drug toxicity | BIOADVANTEX PHARMA INC (CA) | 2009-03-04 | — | — | CN | disclosed |
| WO-2006060578-A2 | NUTRITIONAL SUPPLEMENTS CONTAINING XANTHONE EXTRACTS | XANTHONE PLUS INTERNATIONAL, LLC (US) | 2006-06-08 | — | — | WO | disclosed |
| CN-1507350-A | N-acetylcysteine compositions and methods for treatment and prevention of drug intoxication | ��������ҩ�ɷ�����˾ | 2004-06-23 | — | — | CN | disclosed |
| EP-1301181-A2 | THERAPEUTIC AND PROPHYLACTIC USE OF REDUCED FORMS OF PHARMACEUTICAL COMPOUNDS | Hunter-Fleming Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| EP-1299125-A1 | PRODUCTION, STABILISATION AND USE OF REDUCED FORMS OF PHARMACEUTICAL COMPOUNDS | Hunter-Fleming Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002003972-A2 | THERAPEUTIC AND PROPHYLACTIC USE OF REDUCED FORMS OF PHARMACEUTICAL COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004025-A1 | PRODUCTION, STABILISATION AND USE OF REDUCED FORMS OF PHARMACEUTICAL COMPOUNDS | HUNTER-FLEMING LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
| WO-1999038507-A1 | REVERSAL AND PREVENTION OF CLINICALLY SIGNIFICANT ASPECTS OF AGING THROUGH ORAL USE OF HEPATIC ARTERY VASODILATOR AND OTHER AGENTS WHICH INCREASE HEPATIC OXYGENATION | LE COUTEUR DAVID GEORGE (AU) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135228-B2 | Cysteinyl-proresolving mediators that promote resolution of infection and organ protection | CYSLTR2, FPR2, MSR1 | PTGS1 49/4885GSTK1 208/4885GLO1 1776/4885 |
| US-20170258806-A1 | OXYLIPIN-PEPTIDE CONJUGATED MEDIATORS THAT PROMOTE RESOLUTION OF INFECTION, ORGAN PROTECTION AND TISSUE REGENERATION | FPR2, MSR1, OSBP2 | PTGS1 348/4885GSTK1 319/4885GLO1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.